Gardasil’s Strong Launch May Be Suppressing Merck’s M&A Appetite
The robust growth for Merck's human papillomavirus vaccine Gardasil seen in the first quarter in part reflects initial purchases by state Vaccines for Children programs
The robust growth for Merck's human papillomavirus vaccine Gardasil seen in the first quarter in part reflects initial purchases by state Vaccines for Children programs